Vaxart, Inc. Convertible Notes Payable, Noncurrent
Vaxart, Inc. (VXRT) had Convertible Notes Payable, Noncurrent of $35.28 million as of 2017-12-31, per its 10-Q filed 2018-05-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Notes Payable, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2018-05-15
- 2017-12-31: Convertible Notes Payable, Noncurrent $35.28M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2017-12-31 | $35.28M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |